Breast Cancer Pipeline Review, H1 2013


#166286

524pages

Global Markets Direct

$ 2500

In Stock

 

Breast Cancer Pipeline Review, H1 2013

 

Summary

 

Global Markets Directs, 'Breast Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. Breast Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

 

  • A snapshot of the global therapeutic scenario for Breast Cancer.
  • A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Breast Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

 

  • Identify and understand important and diverse types of therapeutics under development for Breast Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
Introduction 12
Breast Cancer Overview 13
Therapeutics Development 14
Breast Cancer Therapeutics under Development by Companies 16
Breast Cancer Therapeutics under Investigation by Universities/Institutes 37
Late Stage Products 44
Mid Clinical Stage Products 45
Early Clinical Stage Products 46
Discovery and Pre-Clinical Stage Products 47
Breast Cancer Therapeutics Products under Development by Companies 48
Breast Cancer Therapeutics Products under Investigation by Universities/Institutes 83
Companies Involved in Breast Cancer Therapeutics Development 91
Breast Cancer Therapeutics Assessment 335
Drug Profiles 343
Breast Cancer Therapeutics Drug Profile Updates 423
Breast Cancer Therapeutics Discontinued Products 469
Breast Cancer Therapeutics - Dormant Products 477
Breast Cancer Product Development Milestones 505
 

Appendix 513


Number of Products Under Development for Breast Cancer, H1 2013 24
Products under Development for Breast Cancer Comparative Analysis, H1 2013 25
Number of Products under Development by Companies, H1 2013 27
Number of Products under Development by Companies, H1 2013 (Contd..1) 28
Number of Products under Development by Companies, H1 2013 (Contd..2) 29
Number of Products under Development by Companies, H1 2013 (Contd..3) 30
Number of Products under Development by Companies, H1 2013 (Contd..4) 31
Number of Products under Development by Companies, H1 2013 (Contd..5) 32
Number of Products under Development by Companies, H1 2013 (Contd..6) 33
Number of Products under Development by Companies, H1 2013 (Contd..7) 34
Number of Products under Development by Companies, H1 2013 (Contd..8) 35
Number of Products under Development by Companies, H1 2013 (Contd..9) 36
Number of Products under Development by Companies, H1 2013 (Contd..10) 37
Number of Products under Development by Companies, H1 2013 (Contd..11) 38
Number of Products under Development by Companies, H1 2013 (Contd..12) 39
Number of Products under Development by Companies, H1 2013 (Contd..13) 40
Number of Products under Development by Companies, H1 2013 (Contd..14) 41
Number of Products under Development by Companies, H1 2013 (Contd..15) 42
Number of Products under Development by Companies, H1 2013 (Contd..16) 43
Number of Products under Development by Companies, H1 2013 (Contd..17) 44
Number of Products under Development by Companies, H1 2013 (Contd..18) 45
Number of Products under Development by Companies, H1 2013 (Contd..19) 46
Number of Products under Investigation by Universities/Institutes, H1 2013 48
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 49
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 50
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 51
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 52
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 53
Comparative Analysis by Late Stage Development, H1 2013 54
Comparative Analysis by Mid Clinical Stage Development, H1 2013 55
Comparative Analysis by Early Clinical Stage Development, H1 2013 56
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 57
Products under Development by Companies, H1 2013 58
Products under Development by Companies, H1 2013 (Contd..1) 59
Products under Development by Companies, H1 2013 (Contd..2) 60
Products under Development by Companies, H1 2013 (Contd..3) 61
Products under Development by Companies, H1 2013 (Contd..4) 62
Products under Development by Companies, H1 2013 (Contd..5) 63
Products under Development by Companies, H1 2013 (Contd..6) 64
Products under Development by Companies, H1 2013 (Contd..7) 65
Products under Development by Companies, H1 2013 (Contd..8) 66
Products under Development by Companies, H1 2013 (Contd..9) 67
Products under Development by Companies, H1 2013 (Contd..10) 68
Products under Development by Companies, H1 2013 (Contd..11) 69
Products under Development by Companies, H1 2013 (Contd..12) 70
Products under Development by Companies, H1 2013 (Contd..13) 71
Products under Development by Companies, H1 2013 (Contd..14) 72
Products under Development by Companies, H1 2013 (Contd..15) 73
Products under Development by Companies, H1 2013 (Contd..16) 74
Products under Development by Companies, H1 2013 (Contd..17) 75
Products under Development by Companies, H1 2013 (Contd..18) 76
Products under Development by Companies, H1 2013 (Contd..19) 77
Products under Development by Companies, H1 2013 (Contd..20) 78
Products under Development by Companies, H1 2013 (Contd..21) 79
Products under Development by Companies, H1 2013 (Contd..22) 80
Products under Development by Companies, H1 2013 (Contd..23) 81
Products under Development by Companies, H1 2013 (Contd..24) 82
Products under Development by Companies, H1 2013 (Contd..25) 83
Products under Development by Companies, H1 2013 (Contd..26) 84
Products under Development by Companies, H1 2013 (Contd..27) 85
Products under Development by Companies, H1 2013 (Contd..28) 86
Products under Development by Companies, H1 2013 (Contd..29) 87
Products under Development by Companies, H1 2013 (Contd..30) 88
Products under Development by Companies, H1 2013 (Contd..31) 89
Products under Development by Companies, H1 2013 (Contd..32) 90
Products under Development by Companies, H1 2013 (Contd..33) 91
Products under Development by Companies, H1 2013 (Contd..34) 92
Products under Investigation by Universities/Institutes, H1 2013 93
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 94
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 95
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 96
Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 97
Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 98
Products under Investigation by Universities/Institutes, H1 2013 (Contd..6) 99
Products under Investigation by Universities/Institutes, H1 2013 (Contd..7) 100
Bristol-Myers Squibb Company, H1 2013 101
Johnson & Johnson, H1 2013 102
Boehringer Ingelheim GmbH, H1 2013 103
F. Hoffmann-La Roche Ltd., H1 2013 104
Kyowa Hakko Kirin Co., Ltd., H1 2013 105
Celsion Corporation, H1 2013 106
Biogen Idec Inc., H1 2013 107
Amgen Inc., H1 2013 108
Sanofi-Aventis, H1 2013 109
Adherex Technologies Inc., H1 2013 110
AstraZeneca PLC, H1 2013 111
Eli Lilly and Company, H1 2013 112
Viralytics Ltd., H1 2013 113
GlaxoSmithKline plc, H1 2013 114
Bioniche Life Sciences, Inc., H1 2013 115
Tekmira Pharmaceuticals Corp., H1 2013 116
Genentech, Inc., H1 2013 117
Nektar Therapeutics, H1 2013 118
Inovio Biomedical Corporation, H1 2013 119
Watson Pharmaceuticals, Inc., H1 2013 121
Bavarian Nordic A/S, H1 2013 122
MedImmune LLC, H1 2013 123
Biotest AG, H1 2013 124
Daiichi Sankyo Company, Ltd, H1 2013 125
Merck & Co., Inc., H1 2013 126
AbGenomics International, Inc., H1 2013 127
FASgen, Inc., H1 2013 128
A&G Pharmaceutical, Inc., H1 2013 129
Bioneer Corporation, H1 2013 131
Generex Biotechnology Corporation, H1 2013 132
Plexxikon Inc., H1 2013 133
Ipsen S.A., H1 2013 134
MediGene AG, H1 2013 135
Celltrion, Inc., H1 2013 136
Bio-Path Holdings, Inc., H1 2013 137
BioSante Pharmaceuticals, Inc., H1 2013 138
Histogen, Inc., H1 2013 139
ZIOPHARM Oncology, Inc., H1 2013 140
Novartis AG, H1 2013 142
Aphios Corporation, H1 2013 143
Biocon Limited, H1 2013 144
Chong Kun Dang Pharmaceutical, H1 2013 145
Dong-A Pharmaceutical Co., Ltd., H1 2013 146
Eisai Co., Ltd., H1 2013 147
Gedeon Richter Plc., H1 2013 148
GTC Biotherapeutics, Inc., H1 2013 149
GTx, Inc., H1 2013 150
Laboratoires Pierre Fabre SA, H1 2013 151
Nippon Kayaku Co., Ltd., H1 2013 152
Pfizer Inc., H1 2013 153
Sigma-Tau S.p.A., H1 2013 154
Taiho Pharmaceutical Co., Ltd., H1 2013 155
Takara Holdings Inc., H1 2013 156
Teva Pharmaceutical Industries Limited, H1 2013 157
Cell Therapeutics, Inc., H1 2013 158
Enzon Pharmaceuticals, Inc., H1 2013 159
Exelixis, Inc., H1 2013 160
Aduro BioTech, H1 2013 161
Menarini Group, H1 2013 162
Alfacell Corporation, H1 2013 163
CEL-SCI Corporation, H1 2013 164
Celgene Corporation, H1 2013 165
Bayer AG, H1 2013 166
Access Pharmaceuticals, Inc., H1 2013 167
Advaxis, Inc., H1 2013 168
Neogenix Oncology Corporation, H1 2013 169
EntreMed, Inc., H1 2013 171
GW Pharmaceuticals plc, H1 2013 172
Hana Biosciences, Inc., H1 2013 173
Hollis-Eden Pharmaceuticals, Inc., H1 2013 174
Celldex Therapeutics, Inc., H1 2013 175
Momenta Pharmaceuticals, Inc., H1 2013 176
ValiRx Plc, H1 2013 177
AEterna Zentaris Inc., H1 2013 178
IMMUNOMEDICS, INC, H1 2013 179
Lorus Therapeutics Inc, H1 2013 180
Marshall Edwards, Inc., H1 2013 181
Basilea Pharmaceutica Ltd., H1 2013 182
Bionomics Limited, H1 2013 183
MultiCell Technologies, Inc., H1 2013 184
Neuren Pharmaceuticals Limited, H1 2013 185
Northwest Biotherapeutics, Inc., H1 2013 186
Cleveland BioLabs, Inc., H1 2013 187
Oncolytics Biotech Inc., H1 2013 188
OncoVista Innovative Therapies, Inc., H1 2013 189
Compugen Ltd., H1 2013 190
Patrys Limited, H1 2013 191
Peregrine Pharmaceuticals, Inc., H1 2013 192
Critical Outcome Technologies Inc., H1 2013 193
Curis, Inc., H1 2013 194
Medivation, Inc., H1 2013 195
Bionovo, Inc., H1 2013 196
CSL Limited, H1 2013 197
Cytokinetics, Inc, H1 2013 198
Telik, Inc., H1 2013 199
VioQuest Pharmaceuticals, Inc., H1 2013 200
Zenotech Laboratories Limited, H1 2013 201
Regeneron Pharmaceuticals, Inc., H1 2013 202
Oncogenex Pharmaceuticals, Inc., H1 2013 203


Number of Products under Development for Breast Cancer, H1 2013 24
Products under Development for Breast Cancer Comparative Analysis, H1 2013 25
Products under Development by Companies, H1 2013 26
Products under Investigation by Universities/Institutes, H1 2013 47
Late Stage Products, H1 2013 54
Mid Clinical Stage Products, H1 2013 55
Early Clinical Stage Products, H1 2013 56
Discovery and Pre-Clinical Stage Products, H1 2013 57
Assessment by Monotherapy Products, H1 2013 345
Assessment by Combination Products, H1 2013 346
Assessment by Route of Administration, H1 2013 347
Assessment by Stage and Route of Administration, H1 2013 348
Assessment by Molecule Type, H1 2013 350
Assessment by Stage and Molecule Type, H1 2013 351